Navigation Links
FDA Clears a Test for Ovarian Cancer
Date:9/11/2009

Test can help identify potential malignancies, guide surgical decisions

SILVER SPRING, Md., Sept. 11 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer. If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1 result.

OVA1 should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures.

OVA1 uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant.

OVA1 is intended only for women, 18 years and older, who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal.

The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists published recommendations in 2002 for the role of generalist obstetrician-gynecologists in the early detection of ovarian cancer, which included a recommendation of patient referral to a gynecological oncologist when specific indicators of malignancy are present.

These recommendations and later reports indicate that patients with ovarian cancer have improved survival when the surgery is performed by gynecologic oncologists as opposed to general gynecologists or surgeons.

"Tests such as OVA1 personalize and improve public health by providing patients and health care providers with more information to support medical decisions that impact survival rates and reduce surgical complications," said Jeffrey Shuren, M.D., J.D., acting director of the FDA's Center for Devices and Radiological Health.

The FDA reviewed a study of 516 patients, including 269 evaluated by non-gynecological oncologists, which compared OVA1 results with biopsy results. When combined with pre-surgical information, such as radiography and other laboratory tests, results from the OVA1 tests identified additional patients who might benefit from oncology referral who were not identified using pre-surgical information alone.

OVA1 is developed by Vermillion Inc., headquartered in Fremont, Calif., in conjunction with researchers at The Johns Hopkins University in Baltimore.

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
2. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
3. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
4. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
5. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
6. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
7. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
8. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
9. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017  This report by ... central catheters market for the period 2016–2024. The ... updates and information related to market opportunities in ... comprehensive market study demonstrates the various dynamics that ... future status of the global peripherally inserted central ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek ... Potts Law Firm, was recently appointed Liaison Counsel in ... (JCCP) for all Xarelto cases. In this role, Potts ... parties and will actively assist the Court and Co ... with Milstein Adelman Jackson Fairchild & ...
(Date:1/16/2017)... 2017  According to Kalorama Information, the global ... at $4.9 billion for 2016.  The growing number ... aging population with significant diagnostic needs, along with ... the market for the modality.  The healthcare market ... focuses on the worldwide market, providing market size ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening ... January 8 for use by sports teams and the general public. Built in five ... that can also be converted into basketball or pickleball courts. The space is also ...
(Date:1/16/2017)... TX (PRWEB) , ... January 16, 2017 , ... ... dental office , Antoine Dental Center, is currently offering complimentary consultations and financing ... have their teeth examined for bite irregularities and learn about their orthodontic options. ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... manufacturer Prairie Seating. Prairie’s award-winning Reflection® brand of custom seating systems has a ... acquisition provides Permobil with a platform for innovation and growth in the custom ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... announce their recent partnership with an innovator in the wheelchair accessibility industry, ... motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new incentive ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January ... , Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health ... program, The Sharon Kleyne Hour Power of Water, Global Climate Change and Your ...
Breaking Medicine News(10 mins):